New research presented at the 2026 ATS International Conference reveals which patients with obesity and obstructive sleep apnea (OSA) are most likely to benefit from tirzepatide GLP-1 medication.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?
Confirmed Tirzepatide benefits OSA patients with obesity
Yes Patient subgroups identified for better outcomes